دورية أكاديمية
Prognostic value of serum analyses of S-100 beta protein in malignant melanoma.
| العنوان: | Prognostic value of serum analyses of S-100 beta protein in malignant melanoma. |
|---|---|
| المؤلفون: | von Schoultz E; Department of Oncology, Radiumhemmet, Karolinska Hospital, Stockholm, Sweden., Hansson LO, Djureen E, Hansson J, Kärnell R, Nilsson B, Stigbrand T, Ringborg U |
| المصدر: | Melanoma research [Melanoma Res] 1996 Apr; Vol. 6 (2), pp. 133-7. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Lippincott Williams & Wilkins Country of Publication: England NLM ID: 9109623 Publication Model: Print Cited Medium: Print ISSN: 0960-8931 (Print) Linking ISSN: 09608931 NLM ISO Abbreviation: Melanoma Res Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: London : Lippincott Williams & Wilkins Original Publication: Oxford, UK : Rapid Communications of Oxford, 1991- |
| مواضيع طبية MeSH: | Melanoma/*blood , Neoplasm Proteins/*blood , S100 Proteins/*blood , Skin Neoplasms/*blood, Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal ; Female ; Humans ; Immunoradiometric Assay ; Macromolecular Substances ; Male ; Melanoma/pathology ; Middle Aged ; Neoplasm Staging ; Nerve Growth Factors ; Predictive Value of Tests ; Prognosis ; S100 Calcium Binding Protein beta Subunit ; Skin Neoplasms/pathology |
| مستخلص: | S-100 protein was first described in the central nervous system but is also present in malignant melanoma cells. Immunohistochemical detection of S-100 is widely used in the histopathological diagnosis of malignant melanoma. In the present study serum levels of S-100 beta protein were measured in 643 patients with cutaneous malignant melanoma. An immunoradiometric assay with three monoclonal antibodies against bovine S-100 protein beta subunit was used. At the time of blood sampling 553 patients were in clinical stage I, 24 in clinical stage II and 66 in clinical stage III. The overall survival rate was strongly associated with serum levels of S-100 protein. The observed/ expected death ratio was markedly increased with increasing levels of S-100 beta (P < 0.001). A fivefold increase in relative hazard was indicated by a value of S-100 beta exceeding 0.6 microgram/l (P < 0.001) and when this cut-off level was used S-100 beta had additional prognostic value independent of clinical stage (P < 0.001). Our data strongly suggest that S-100 beta in serum is an independent prognostic marker that may be useful in identifying high-risk cases and monitoring response to therapy in patients with malignant melanoma. |
| المشرفين على المادة: | 0 (Antibodies, Monoclonal) 0 (Macromolecular Substances) 0 (Neoplasm Proteins) 0 (Nerve Growth Factors) 0 (S100 Calcium Binding Protein beta Subunit) 0 (S100 Proteins) |
| تواريخ الأحداث: | Date Created: 19960401 Date Completed: 19961107 Latest Revision: 20191024 |
| رمز التحديث: | 20240627 |
| DOI: | 10.1097/00008390-199604000-00008 |
| PMID: | 8791271 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 0960-8931 |
|---|---|
| DOI: | 10.1097/00008390-199604000-00008 |